Abstract
The wetland plant Ludwigia perennis is a member of the Ongraceae genus. Many components of this plant offer a range of traditional therapeutic benefits. The major goal of this study is to identify the pharmacological properties of the root extract of the plant. The antioxidant activity was evaluated using DPPH, the total phosphomolybdenum test, and the hydroxyl radical scavenging assay. Using the α-amylase and α-glucosidase tests, anti-diabetic efficacy was found to exist. To identify the existence of anti-nutritional substances, the total phytic acid content, oxalate content, saponin content, and alkaloid content were examined. To comprehend the anticancer activity, HeLa cell lines was used for MTT testing and AO/EB dual labelling. A rat model analysis of anti-inflammatory activity was conducted. The IC₅₀ value of the standard in the DPPH assay was 49.74µg/mL, and the root extract was 55.4µg/mL. In phosphomolybdenum assay, the IC₅₀ value of the standard was 33.73 µg/mL, and root extract was 34.13µg/mL. The IC₅₀ value of the reference compound in the hydroxyl radical scavenging assay was 55.6µg/mL, and that of the root extract was 69.06µg/mL. The IC50 of the standard in the α-amylase inhibitory assay is 394.48µg/mL, and the extract's IC50 is 327.82µg/mL, respectively. The IC50 of the standard in the α-glucosidase inhibitory assay was 394.06µg/mL, and the extract's IC50 was 361.58µg/mL, respectively. Anti-nutrients content such as alkaloids was 20%, oxalate 2.20%, phytate 3.25% and saponin 22% respectively. The IC50 of HeLa cells treated with root extract was 210µg/mL.Compared to the 59.44% inhibition generated by 10mg/kg of the standard medicine, indomethacin, the chloroform root extract of Ludwigia perennis provided 22.03% and 46.68% inhibition of paw edema at doses of 50mg/kg and 250mg/kg, respectively.These facts imply that the plant may be used to create novel medications.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have